AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Photocure ASA

Share Issue/Capital Change Mar 14, 2022

3714_rns_2022-03-14_5d361b21-b1d9-4170-a116-c3c779b443d1.html

Share Issue/Capital Change

Open in Viewer

Opens in native device viewer

Photocure ASA: Exercise of employee share options and share capital increase

Photocure ASA: Exercise of employee share options and share capital increase

Oslo, Norway, 14 March 2022: Participants in Photocure ASA's ("Photocure" or the

"Company") share option program have on 14 March 2022 exercised a total of 2,750

options distributed as follows:

· 500 options exercised according to the option program for 2019 at a strike

price of NOK 50.72;

· 1,250 options exercised according to the option program for 2020 at a strike

price of NOK 81.41; and

· 1,000 options exercised according to the option program for 2020 at a strike

price of NOK 87.39.

Each option gives a right to receive one share in the Company. The share options

are described in note 7 and 23 in Photocure's annual financial statements for

Following the exercise, the Board of Directors, pursuant to authorisation

granted by the Company's Annual General Meeting, has decided to increase the

Company's share capital by NOK 1,375 by issuing 2,750 new shares, of par value

NOK 0.50. Subsequent to the transaction, Photocure's share capital will be NOK

13,488,285 divided into 26,976,570 shares, each share having a par value of NOK

0.50 and carrying one vote in the Company's general meeting.

No primary insiders have exercised share options.

For further information, please contact:

Photocure

CFO Erik Dahl

Tel: +47 450 55 000

Email: [email protected]

About Photocure ASA

Photocure: The Bladder Cancer Company delivers transformative solutions to

improve the lives of bladder cancer patients. Our unique technology, making

cancer cells glow bright pink, has led to better health outcomes for patients

worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo

Stock Exchange (OSE: PHO). For more information, please visit us at

www.photocure.com, www.hexvix.com or www.cysview.com

All trademarks mentioned in this release are protected by law and are registered

trademarks of Photocure ASA.

This information is subject to the disclosure requirements pursuant to the

market abuse regulation article 19 and 5-12 of the Norwegian Securities Trading

Act.

Talk to a Data Expert

Have a question? We'll get back to you promptly.